Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19

Simple item page
dc.contributor.authorElmunzer, B. Joseph
dc.contributor.authorWolf, Bethany J.
dc.contributor.authorScheiman, James M.
dc.contributor.authorTierney, William M.
dc.contributor.authorTaylor, Jason R.
dc.contributor.authorNorth American Alliance for the Study of Digestive Manifestations of COVID-19
dc.contributor.departmentCommunity and Global Health, Richard M. Fairbanks School of Public Health
dc.date.accessioned2024-10-24T15:20:44Z
dc.date.available2024-10-24T15:20:44Z
dc.date.issued2021
dc.eprint.versionFinal published version
dc.identifier.citationElmunzer BJ, Wolf BJ, Scheiman JM, Tierney WM, Taylor JR; North American Alliance for the Study of Digestive Manifestations of COVID-19. Association Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19. Gastroenterology. 2021;160(4):1417-1422.e14. doi:10.1053/j.gastro.2020.11.007
dc.identifier.urihttps://hdl.handle.net/1805/44213
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1053/j.gastro.2020.11.007
dc.relation.journalGastroenterology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectCOVID-19
dc.subjectHistamine 2 Receptor Antagonists
dc.subjectProton Pump Inhibitor
dc.subjectSARS-CoV-2
dc.titleAssociation Between Preadmission Acid Suppressive Medication Exposure and Severity of Illness in Patients Hospitalized With COVID-19
dc.typeArticle
ul.alternative.fulltexthttps://pmc.ncbi.nlm.nih.gov/articles/PMC7659802/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Elmunzer2020Association-PP.pdf
Size:
565.51 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Community and Global Health Works